A general method was described to synthesize a highly hydrophobic cyclic peptide,cyclo[LWLWLWLWLQ]where underlines indicate D-configuration of the amino acid,by a two-step solid-phase/solution synthesis strategy.The l...A general method was described to synthesize a highly hydrophobic cyclic peptide,cyclo[LWLWLWLWLQ]where underlines indicate D-configuration of the amino acid,by a two-step solid-phase/solution synthesis strategy.The linear decapeptide was assembled by standard Boc chemistry on solid-phase and subsequently cyclized in solution with high efficiency and reproducibility. In subsequent purification by semi-preparative HPLC,50%(v/v) DMF/H_2O was employed as the solvent to overcome the difficulty of solubilization...展开更多
In order to study the effect of dihydroxyacetophenone ( DHAP) on pulmonary hemodynamicsand its relationship to plasma atrial natriuretic peptide (ANP) as well as adenosine cyclophosphates in chron-ic obstractive pulmo...In order to study the effect of dihydroxyacetophenone ( DHAP) on pulmonary hemodynamicsand its relationship to plasma atrial natriuretic peptide (ANP) as well as adenosine cyclophosphates in chron-ic obstractive pulmonary disease (COPD) , right heart catheterization was used to examine some parametersof hemodynamics in 11 COPD patients before and after the application of DHAP, and at the same time ra-dioimmunoassay was used to measure the plasma ANP and cyclo-adenosine monophosphate/cyclic guanosinemonophosphate (cAMP/cGMP) . The results showed that DHAP 640 mg given intravenously could decreasemean pulmonary arterial pressure, pulmonary vascular resistance and systemic vascular resistance ( P <0 . 05) , but increase cardiac output from 4. 10 ±1 . 08 L/min to 5.13 ± 1 . 19 L/min ( P>0. 05) and without af-fecting systemic arterial blood pressure ( P >0. 05) as well as blood gas analysis; it could also reduce theplasma ANP and cGMP Ievel from 0. 73 ± 0. 42 pg/ml to 0. 41 ± 0. 33 pg/ml ( P<0. 01 ) and trom 9 . 82 ± 5. 75pm/ml to 8. 01 ± 4. 80 pm/ml( P< 0. 05) respectively, but did not affect the plasma cAMP level ( P>0. 05) .It is suggested that DHAP may relax pulmonary vessels by adjusting the ratio of cAMP to cGMP, and the low-ering of plasma ANP level might be a secondary reaction. So DHAP was considered a quick-acting, safe andpotential drug in treating pulmonary arterial hypertension by COPD.展开更多
基金supported by National Natural Science Foundation(No.30672546)Shanghai Municipal Committee of S & T(No.0652nm013)National Key Basic Research Program of China(No.2007CB935800)
文摘A general method was described to synthesize a highly hydrophobic cyclic peptide,cyclo[LWLWLWLWLQ]where underlines indicate D-configuration of the amino acid,by a two-step solid-phase/solution synthesis strategy.The linear decapeptide was assembled by standard Boc chemistry on solid-phase and subsequently cyclized in solution with high efficiency and reproducibility. In subsequent purification by semi-preparative HPLC,50%(v/v) DMF/H_2O was employed as the solvent to overcome the difficulty of solubilization...
文摘In order to study the effect of dihydroxyacetophenone ( DHAP) on pulmonary hemodynamicsand its relationship to plasma atrial natriuretic peptide (ANP) as well as adenosine cyclophosphates in chron-ic obstractive pulmonary disease (COPD) , right heart catheterization was used to examine some parametersof hemodynamics in 11 COPD patients before and after the application of DHAP, and at the same time ra-dioimmunoassay was used to measure the plasma ANP and cyclo-adenosine monophosphate/cyclic guanosinemonophosphate (cAMP/cGMP) . The results showed that DHAP 640 mg given intravenously could decreasemean pulmonary arterial pressure, pulmonary vascular resistance and systemic vascular resistance ( P <0 . 05) , but increase cardiac output from 4. 10 ±1 . 08 L/min to 5.13 ± 1 . 19 L/min ( P>0. 05) and without af-fecting systemic arterial blood pressure ( P >0. 05) as well as blood gas analysis; it could also reduce theplasma ANP and cGMP Ievel from 0. 73 ± 0. 42 pg/ml to 0. 41 ± 0. 33 pg/ml ( P<0. 01 ) and trom 9 . 82 ± 5. 75pm/ml to 8. 01 ± 4. 80 pm/ml( P< 0. 05) respectively, but did not affect the plasma cAMP level ( P>0. 05) .It is suggested that DHAP may relax pulmonary vessels by adjusting the ratio of cAMP to cGMP, and the low-ering of plasma ANP level might be a secondary reaction. So DHAP was considered a quick-acting, safe andpotential drug in treating pulmonary arterial hypertension by COPD.
